PofoliaShared via Pofolia

ACS Omega· 2026Q1

Skin-on-a-Chip for Cosmetic Safety Assessment: From Reconstructed Skin Models to Regulatory Translation

Qian Zhu, Wenhui Liu, Xinjie Lv, Xixi Wu

Short summary

Skin-on-a-chip (SoC) models are proposed as a higher-tier complement to established reconstructed human epidermis (RhE) and skin (RhS) models for cosmetic safety assessment, but require significant validation for regulatory acceptance.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Skin-on-a-chip (SoC) models can address specific cosmetic safety questions not fully resolved by reconstructed human epidermis (RhE) or skin (RhS) models.
  • SoC testing is recommended only when established methods leave decision-relevant uncertainty.
  • Translating SoC models for regulatory acceptance requires four stages: analytical validation, biological validation, context-of-use qualification, and regulatory acceptance.
  • Decision-ready readouts from SoC models necessitate traceable calibration, explicit units, prespecified normalization, drift control, variability estimates, comparator agreement, and quantitative acceptance criteria.

AI-generated from the title and abstract; the full text is not read.

Abstract

Abstract Cosmetic safety assessment increasingly relies on human-relevant nonanimal methods that support mechanistic interpretation and align with a defined decision context. Reconstructed human epidermis (RhE) supports accepted irritation and corrosion procedures. Reconstructed human skin (RhS) and full-thickness equivalents provide tissue-level comparators for dermal architecture, penetration, and recovery. These models are distinct comparator classes. Rather than cataloging skin-on-a-chip (SoC) architectures, this review assigns an appropriate comparator to each cosmetic-safety question. It then defines the residual uncertainty that may justify SoC testing. It also specifies required readouts and evidence thresholds for a prespecified decision. Vascular and immune modules, controlled topical dosing, and multiorgan coupling are considered only when they address unresolved time course, exposure route, tissue context, or mechanism. Decision-ready readouts require traceable calibration, explicit units, prespecified normalization, drift control, variability estimates, comparator agreement, and quantitative acceptance criteria. No reviewed skin SoC has broad regulatory acceptance for routine cosmetic-safety decisions. Translation therefore requires four distinct stages: analytical validation, biological validation, context-of-use qualification, and regulatory acceptance. Current evidence supports SoC mainly as a higher-tier complement when established methods leave a decision-relevant uncertainty.

The authors' abstract, as published at the source. ACS Omega, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Small AnimalsVeterinary